ERBB2 and gastroesophageal junction adenocarcinoma: The favorable hematologic toxicity profile of FOLFOX-A as compared to FLOT is worthy of further study of FOLFOX-A as a first-line therapy for metastatic HER2-negative gastric/GEJ adenocarcinoma.